Case studies patent

Good case studies dealing with patent issues.

1. Patent related case studies
Dr UrmilaM. Aswar
&
Miss ShradhaH.
Dept. of Pharmacology, SIOP, Narhe

2. Case Study -1
Novartis Vs Union of India and
others
4/8/2015 2

3. Novartis
Gleevec
1993
(Imatinib)
2006 Sec .
3(d)
2007, 2009
1998 (Imatinib
Mesylate)
Final decision
2013
Novartis
Chronic myeloid
leukemia
4/8/2015 3
The case was to patent Gleevecin India

4. ParameterGleevec Generic
version of
Gleevec
Company Novartis Natco(local
company)
Nature Expensive Least
expensive
Cost 1tablet-
2200 Rs
1tablet-
500 Rs
Preference16000 people 300000 people
4/8/2015 4

5. Case study –2
Basmati Rice
4/8/2015 5
Golden
Basmati
Raw
Basmati
Silky Raw Basmati

6. Basmati Rice
4/8/2015 6
Patenting Authority
USPatent
International market
Kasmati Texmati
American Company: RiceTecInc, (Basmati 867)
Patent application1995 US Patent in 1997

7. 4/8/2015 7
Opposed by Government
of India
In 2000 re-examination /indepth
analysis of application by high level
inter-ministerial group
Patentcancelledin2000and
Indiawonthecaseonbasisof
violationofGIunderTRIPS.

8. Case study –3
NEEM (Azadiractaindica)
•N–Natures
•E-EcoFriendly
•E-Economical
•M-Miracle
4/8/2015 8

9. 4/8/2015 9
1971
Robert
Larson
Pesticidal neem
extract (1985)
Multinational chemical
corporation, W R
Grace and Co
Sold in 1988

10. 4/8/2015 10
1990
•Multinational chemical corporation,
W R Grace and Co (Neem-based bio-
pesticides )
1994
•European Patent Office (EPO)
granted a patent
1995
•Opposed By VandanaShiva of the
Research Foundation for Science,
Technology and Ecology(RFSTE)
2000
•EPO revoked patent on the basis of
lack of inventive step and novely.

11. Case study –4
Turmeric (Curcuma longa)
4/8/2015 11

12. 4/8/2015 12
(1993) Patent application by
University of Mississippi
Medical Center
(1995) USPTO granted patent
for use of turmeric in wound
healing
Opposed by India's
Council of Scientific and
Industrial Research(CSIR)
1997 Patent cancelled

13. Case study -5
Natco vsBayer case of compulsary
license
4/8/2015 13
Vs

14. 4/8/2015 14
•Patent grant
by India
•Natcoand
voluntary
license
•Patent
application
•Bayer
invented
Sorafenib
1990 1999
20082011

15. Cost and Patient Benefitted
•Cost of Naxaverby
Bayer: Rs 2.85 L /
month
•Patient: 2%
•BY Natco: Rs 8900/
month.
•Free to needy

16. 4/8/2015 16
Natcofiled application for compulsory license
2012 Natcoreceived grant for compulsory
license (6% royalty)
2013 modification in royalty 7%
Sec -84